Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC_EX:A61K39/44

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2021/078939RNA OLIGONUCLEOTIDES FOR PREVENTING AGGREGATION OF PROTEINS
WO 29.04.2021
Int.Class A61K 9/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
14Particulate form, e.g. powders
Appl.No PCT/EP2020/079882 Applicant UNIVERSITÄT WIEN Inventor ZAGROVIC, Bojan
A composition comprising a protein and at least one single-stranded linear RNA oligonucleotide with an unfolded tertiary structure, which is characterized by: a) a relative content of each of the nucleotides A, C, U, and G, which is the number of each of the nucleotides per total nucleotide number in the oligonucleotide, which relative content is the same ±10% (number of nucleotides per total nucleotide number) as compared to the relative content of the respective nucleotide in a reference; and/or b) a relative content of at least 50% (number of nucleotides per total nucleotide number) of one type of nucleotide selected from the group consisting of nucleotides A, C, U, and G, which exhibits the highest relative content (number of each of the nucleotides per total nucleotide number) in a reference; wherein the reference consists of a native mRNA or a set of different RNA sequences that covers all RNA sequences allowed by the universal genetic code, each encoding an amino acid sequence of at least three amino acids within a p re-determined aggregation-prone target region of said protein, wherein the oligonucleotide has a length which is the same length as the reference, or longer.
2.112618726一种抗体缀合物、增强抗体分子免疫效应功能的方法
CN 09.04.2021
Int.Class A61K 47/60
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
56the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
59obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
60the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
Appl.No 202011516850.9 Applicant 江南大学 Inventor 吴志猛
本发明公开了一种抗体缀合物、增强抗体分子免疫效应功能的方法。所述抗体缀合物由抗体分子经半抗原衍生物分子修饰所得,所述半抗原衍生物由半抗原、连接臂和耦合域组成。本发明通过温和简便的方法将半抗原衍生物修饰在抗体分子上,所获得的抗体缀合物不仅保留了原有抗体的优良亲和水平,还可以招募相应的特异性天然抗体至肿瘤细胞上,从而达到显著提高抗体ADCC和CDC等免疫效应功能的目的。最重要的是,本发明还通过对连接臂长度的优化,优化得到了SMCC‑PEG3‑Rha这一半抗原衍生物。相比于其它已报道的抗体分子,SMCC‑PEG3‑Rha修饰的抗体,具备更加突出的免疫效应功能。
3.20210084962COATED EGG YOLK CORES, METHODS OF MAKING AND METHODS OF USE THEREOF
US 25.03.2021
Int.Class A23P 20/10
AHUMAN NECESSITIES
23FOODS OR FOODSTUFFS; THEIR TREATMENT, NOT COVERED BY OTHER CLASSES
PSHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
20Coating of foodstuffs; Coatings therefor; Making laminated, multi-layered, stuffed or hollow foodstuffs
10Coating with edible coatings, e.g. with oils or fats
Appl.No 17110585 Applicant WISCONSIN ALUMNI RESEARCH FOUNDATION Inventor JORDAN MARSHALL SAND

A method of making coated avian egg yolk cores includes providing dried avian egg yolk cores having a diameter of 100 to 1500 micrometers, applying avian egg albumen to the dried avian egg yolk cores to provide the coated avian egg yolk cores, and optionally drying the coated avian egg yolk cores, wherein the ratio of dry avian egg albumen to dried avian egg yolk in the coated avian egg yolk cores is 1:10 to 10:1. Also included are the coated avian egg yolk cores, food and feed additives containing the coated avian egg yolk cores and food and feed compositions containing the coated avian egg yolk cores.

4.WO/2021/055658IMPLANIMPLANTABLE SCAFFOLDS AND USES THEREOF FOR IMMUNOTHERAPY OTHER USES
WO 25.03.2021
Int.Class A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
Appl.No PCT/US2020/051363 Applicant THE REGENTS OF THE UNIVERSITY OF CALIFORNIA Inventor BUTTE, Manish J.
An implantable or injectable scaffold comprising immunostimulatory compounds and a suppressor of regulatory T cell induction is provided for use in immunotherapy treatments, including the treatment of cancers and other tumors, in particular solid tumors including inoperable tumors, as well as for other applications of immune enhancement and/or suppression.
5.WO/2021/035310TARGETED DENDRIMER CONJUGATES
WO 04.03.2021
Int.Class A61K 47/56
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
56the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
Appl.No PCT/AU2020/050910 Applicant STARPHARMA PTY LTD Inventor OWEN, David
Provided herein are dendrimer-targeting agent conjugates comprising a dendrimer, the dendrimer comprising a core unit and lysine or lysine analogue building units, a HER2 targeting agent which is a peptidic moiety having a molecular weight of up to about 80 kDa and comprising an antigen-binding site, which is covalently linked by a spacer group, and a therapeutic agent which is covalently linked to a surface building unit of the dendrimer. Also provided herein are compositions comprising the conjugates, and therapeutic methods using the conjugates, particularly for treating cancer.
6.WO/2021/034943IN VIVO IMMUNOIMAGING OF INTERLEUKIN-12
WO 25.02.2021
Int.Class A61K 39/44
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
44Antibodies bound to carriers
Appl.No PCT/US2020/047016 Applicant WAYNE STATE UNIVERSITY Inventor VIOLA, Nerissa
Compositions and methods for in vivo immunoimaging IL-12 as a marker of IL- 12-producing activated antigen presenting cells (APCs) in a subject are provided according to aspects of the present disclosure which include: administering a labeled-antibody conjugate to a subject, wherein the labeled-antibody conjugate includes 1) an antibody or antibody fragment that specifically binds to IL-12, and 2) a detection label conjugated to the antibody or antibody fragment, wherein the detection label is a radionuclide tracer, fluorophore, or nanoparticle, and wherein the labeled- antibody conjugate specifically binds to IL-12; and detecting the presence of the labeled-antibody conjugate in the subject in vivo by imaging. According to embodiments of the present disclosure, the subject is human and the antibody or antibody fragment specifically binds to human IL-12.
7.1020210014615나노입자 구조체
KR 09.02.2021
Int.Class A61K 9/51
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
48Preparations in capsules, e.g. of gelatin, of chocolate
50Microcapsules
51Nanocapsules
Appl.No 1020200185305 Applicant 서울대학교산학협력단 Inventor 현택환
나노입자 구조체가 제공된다. 상기 나노입자 구조체는, 자성 나노입자들이 어셈블된 클러스터를 포함하는 코어 및 상기 코어 표면에 위치하고 세리아 나노입자들을 포함하는 쉘을 포함한다. 상기 자성 나노입자들 중에서 어느 하나의 자성 나노입자는 상기 자성 나노입자들 중에서 적어도 하나의 다른 자성 입자와 접촉하고, 상기 세리아 나노입자들은 상기 코어와 접촉한다.
8.112341542一种3-羟基丁酰化修饰蛋白质药物及其制备方法和应用
CN 09.02.2021
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No 202110020782.5 Applicant 清华大学 Inventor 陈国强
本发明涉及医药技术领域,公开了一种3‑羟基丁酰化修饰蛋白质药物(例如抗体)及其制备方法和应用,特别是一种3‑羟基丁酰化修饰抗体及其制备方法和应用。发明人经过大量实验发现,3‑羟基丁酸及其类似物修饰蛋白质药物(例如抗体)后,可以显著提高蛋白质药物的热稳定性、对蛋白酶水解的抗性,降低蛋白质药物的等电点,并显著延长其在受试者体内的半衰期,进而提高其药效。修饰后所得蛋白质药物在科研和临床方面具有广阔的应用前景和较高的商业价值。
9.112334154基于金纳米颗粒-适配体缀合物的抗体载体及其制备方法
CN 05.02.2021
Int.Class A61K 39/44
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
44Antibodies bound to carriers
Appl.No 201980028325.1 Applicant 恩斯生物技术有限公司 Inventor 李刚奭
本发明涉及基于金纳米颗粒(AuNP)‑适配体缀合物的抗体载体及其制备方法。根据本发明所述的抗体载体通过将免疫球蛋白G(IgG)Fc结构域特异性适配体或荧光素异硫氰酸酯(FITC)特异性适配体与AuNP结合来制备,并且可以通过将待递送的抗体与适配体特异性结合而将抗体递送至细胞核、细胞质和线粒体。另外,由于使用具有极低细胞毒性的AuNP,因此抗体载体不仅对人体无害,而且还可以通过反射各种波长的光来容易地检测细胞中的位置,因此有望有效地用于诊断或治疗疾病。
10.20210023217PROTEINS MODIFIED WITH (AMINO) MONOSACCHARIDE-BIOTIN ADDUCT
US 28.01.2021
Int.Class A61K 39/44
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
44Antibodies bound to carriers
Appl.No 17067691 Applicant GAVISH-GALILEE BIO APPLICATIONS, LTD. Inventor Jacob PITCOVSKI

A protein, e.g. an antibody, coated with a non-immunogenic molecule selected from an amino-monosaccharide-biotin adduct or a monosaccharide-biotin adduct is disclosed, wherein the coated protein, which has diminished immunogenicity relative to the uncoated protein and intact biological activity, enables, for example, cross-species vaccination.